IDH1R132H peptide vaccine / German Cancer Research Center - LARVOL DELTA

AMPLIFY-NEOVAC: AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (clinicaltrials.gov) - P1 | N=69 | Completed | Sponsor: German Cancer Research Center | Active, not recruiting ➔ Completed

Trial completion • Brain Cancer • CNS Tumor • Glioma • Malignant Glioma • Oncology • Solid Tumor • ATRX

AMPLIFY-NEOVAC: AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: German Cancer Research Center | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2024 ➔ Dec 2024 | Trial primary completion date: Sep 2023 ➔ Sep 2024

Checkpoint inhibition • Combination therapy • Enrollment closed • IO biomarker • Trial completion date • Trial primary completion date • Tumor mutational burden • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • ATRX

Large scale identification, tracking and characterization of vaccine-induced neoepitope-specific T cell receptors in patients with IDH1-mutant glioma (CIMT 2024) - "The ongoing phase 1 “window-of-opportunity” clinical trial NOA21 assesses safety, tolerability and immunogenicity of the long IDH1R132H peptide vaccine alone and in combination with Avelumab. A subset of these CD4(+)-derived TCRs shows very strong affinity to pMHC, enabling them to work in a co-receptor independent fashion in CD8+ TCR-transduced T cells in vitro. We were able to rapidly identify and validate reactivity of 104 TCRs, improving our understanding of the mechanism of action of the IDH1R132H long peptide vaccine and supporting design of future vaccine or cell-based therapeutic approaches for patients with IDH1-mutant gliomas."

Clinical • IO biomarker • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • CD40LG • CD8 • IDH1

Large scale identification, tracking and characterization of vaccine-induced neoepitope- specific T cell receptors in patients with IDH1-mutant glioma (CIMT 2024) - "The ongoing phase 1 “window-of-opportunity” clinical trial NOA21 assesses safety, tolerability and immunogenicity of the long IDH1R132H peptide vaccine alone and in combination with Avelumab. A subset of these CD4(+)-derived TCRs shows very strong affinity to pMHC, enabling them to work in a co-receptor independent fashion in CD8+ TCR-transduced T cells in vitro. We were able to rapidly identify and validate reactivity of 104 TCRs, improving our understanding of the mechanism of action of the IDH1R132H long peptide vaccine and supporting design of future vaccine or cell-based therapeutic approaches for patients with IDH1-mutant gliomas."

Clinical • IO biomarker • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • CD40LG • CD8 • IDH1

RESIST: IDH1 Peptide Vaccine for Recurrent Grade II Glioma (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Katy Peters, MD, PhD | Active, not recruiting ➔ Completed

Trial completion • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor